# US 2019/0375941 A1 · Compounds as fluorescent probes, synthesis and applications thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375941 A1
- Document ID: US20190375941A1
- Status: Published application
- Kind: A1
- Application number: 16/130,448
- Filed: 2018-09-13
- Published: 2019-12-12
- Earliest claimed: 2018-06-11
- Assignees: The Institute for Stem Cell Biology and Regenerative Medicine (Instem)
- Applicants: Institute for Stem Cell Biology and Regenerative Medicine (inStem)
- Inventors: Akash GULYANI; Sufi Oasim RAJA; Gandhi SIVARAMAN
- Web page: https://patentgrep.com/patent/US20190375941A1

## CPC

- C09B 23/02: the polymethine chain containing an odd number of >CH- {or >C[alkyl]-} groups
- C09B 23/105: {two >CH- groups}
- C09B 23/0066: {the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)}
- C09B 23/107: {four >CH- groups}
- G01N 33/5076: {involving cell organelles, e.g. Golgi complex, endoplasmic reticulum}
- G01N 33/582: {with fluorescent label}
- C09B: ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to chemical dyes useful for staining and imaging of cells. In particular, the disclosure relates to compound of Formula I, method of preparation thereof, and it's use as a fluorescent probe for staining and/or imaging mitochondria in cells, tissues or animals, resulting in a range of applications including, but not limiting, to sensing local ordering or viscosity of mitochondria, tracking mitochondrial mobility, comparing & evaluating mitochondrial function, local ordering, microviscosity and dynamics. Said dyes have additional advantages including, but not limiting, to low toxicity, longer shelf-life, generate little or no reactive species upon long term light irradiation and do not perturb the functionality of the mitochondria in cells compared to prior art dyes.

## Claims

### Claim 1

A compound of Formula I
wherein,
‘R1’ is selected from a group consisting of hydrogen, dialkyl amino, diaryl amino and alkoxy;
‘R2’, ‘R3’, ‘R4’, ‘R5’ and ‘R6’ are individually selected from a group consisting of hydrogen, alkoxy and alkyl;
‘X’ is selected from a group consisting of I, Cl, Br and F; and
‘Linker’ is selected from a group consisting of alkenylene moiety (—CH═CH—), alkadienyl group (—CH═CH—CH═CH—).

### Claim 2 (depends on 1)

The compound of Formula I as claimed in claim 1, wherein said compound is Formula II
and the Formula II compound is selected from a group consisting of:
Formula II
compounds
R1
R2
R3
R4
R5
R6
Linker
HC-1
—N(CH3)2
—H
—H
—CH3
—CH3
—CH3
—CH═CH—
HC-2
—N(CH3)2
—H
—H
—CH3
—CH3
—CH3
—CH═CH—CH═CH—
HC-3
—N(Ph)2
—H
—H
—CH3
—CH3
—CH3
—CH═CH—
HC-4
—O—CH3
—H
—H
—CH3
—CH3
—CH3
—CH═CH—
HC-5
—H
—O—CH3
—O—CH3
—CH3
—CH3
—CH3
—CH═CH—
HC-6
—O—CH3
—O—CH3
—O—CH3
—CH3
—CH3
—CH3
—CH═CH—
HC-7
—N(CH3)2
—H
—H
—C2H5
—CH3
—CH3
—CH═CH—
HC-8
—N(CH3)2
—H
—H
—C6H13
—CH3
—CH3
—CH═CH—
HC-9
—O—CH3
—H
—H
—C6H13
—CH3
—CH3
—CH═CH—
HC-10
—O—C6H13
—H
—H
—CH3
—CH3
—CH3
—CH═CH—
HC-11
—O—C10H21
—H
—H
—CH3
—CH3
—CH3
—CH═CH—
HC-12
—O—C12H25
—H
—H
—CH3
—CH3
—CH3
—CH═CH—
HC-13
—N(CH3)2
—H
—H
—C6H13
—CH3
—CH3
—CH═CH—CH═CH—

### Claim 3 (depends on 1)

The compound of Formula I as claimed in claim 1, wherein the compound is selected from a group consisting of:
(E)-2-(4-(Dimethylamino)styryl)-1,1,3-trimethyl-1H-benzo[e]indol-3-ium iodide [HC-1];
2-((1E,3E)-4-(4-(Dimethylamino)phenyl)buta-1,3-dien-1-yl)-1,1,3-trimethyl-1H-benzo [e]indol-3-ium iodide [HC-2];
(E)-2-(4-(diphenylamino)styryl)-1,1,3-trimethyl-1H-benzo[e]indol-3-ium iodide [HC-3];
(E)-2-(4-methoxystyryl)-1,1,3-trimethyl-1H-benzo[e]indol-3-ium iodide [HC-4];
(E)-2-(3,5-dimethoxystyryl)-1,1,3-trimethyl-1H-benzo[e]indol-3-ium iodide [HC-5];
(E)-1,1,3-trimethyl-2-(3,4,5-trimethoxystyryl)-1H-benzo[e]indol-3-ium iodide [HC-6];
(E)-2-(4-(dimethylamino)styryl)-3-ethyl-1,1-dimethyl-1H-benzo[e]indol-3-ium iodide [HC-7];
(E)-2-(4-(dimethylamino)styryl)-3-hexyl-1,1-dimethyl-1H-benzo[e]indol-3-ium iodide [HC-8];
(E)-3-hexyl-2-(4-methoxystyryl)-1,1-dimethyl-1H-benzo[e]indol-3-ium iodide [HC-9];
(E)-2-(4-(hexyloxy)styryl)-1,1,3-trimethyl-1H-benzo[e]indol-3-ium iodide [HC-10];
(E)-2-(4-(decyloxy)styryl)-1,1,3-trimethyl-1H-benzo[e]indol-3-ium iodide [HC-11];
(E)-2-(4-(dodecyloxy)styryl)-1,1,3-trimethyl-1H-benzo[e]indol-3-ium iodide [HC-12]; and
2-((1E,3E)-4-(4-(dimethylamino)phenyl)buta-1,3-dien-1-yl)-3-hexyl-1,1-dimethyl-1H-benzo[e]indol-3-ium iodide [HC-13].

### Claim 4 (depends on 1)

A process for preparing the compound of Formula I as defined in claim 1, comprising the step of reacting a compound of Formula III with a substituted or unsubstituted aldehyde derivative in presence of anhydrous ethanol and piperidine under reflux conditions for a time period ranging from about 2 hours to about 3 hours,
wherein the compound of Formula III is
wherein
‘R4’, ‘R5’ and ‘R6’ are individually selected from a group consisting of hydrogen, alkoxy and alkyl; and
‘X’ is selected from a group consisting of I, Cl, Br and F.

### Claim 5 (depends on 4)

The process as claimed in claim 4, wherein the compound of Formula III is selected from a group consisting of 1,1,2-trimethyl-1H-benzo[e]indolium iodide, 3-ethyl-1,1,2-trimethyl-1H-benz[e]indolium iodide and 3-hexyl-1,1,2-trimethyl-1H-benzo[e]indol-3-ium iodide; and the substituted or unsubstituted aldehyde derivative is selected from a group consisting of 4-(dimethylamino)benzaldehyde, 4-(diphenylamino) benzaldehyde, 4-methoxybenzaldehyde, 3,5-dimethoxybenzaldehyde, 3,4,5-trimethoxy benzaldehyde, 4-hexyloxybenzaldehyde, 4-decyloxybenzaldehyde, 4-dodecyloxybenzaldehyde and 4-(dimethylamino)cinnamaldehyde.

### Claim 6 (depends on 1)

The compound as claimed in claim 1, wherein the compound of Formula I is useful as a fluorescent probe in applications selected from a group consisting of staining and/or imaging mitochondria in eukaryotic cells, tissues or animals, sensing local ordering or viscosity of mitochondria in eukaryotic cells, tissues or animals, tracking mitochondrial mobility in eukaryotic cells, tissues or animals, comparing and evaluating mitochondrial function, order and dynamics in eukaryotic cells, tissues or animals, and combinations thereof.

### Claim 7 (depends on 6)

The compound as claimed in claim 6, wherein the eukaryotic cells are live primary cells, induced pluripotent cells (iPCs) or a combination thereof; wherein the eukaryotic cells are from human origin, mouse origin or other animal origin; and wherein the eukaryotic cells are selected from a group consisting of cells in culture, cultured cells, cells from tissue and combinations thereof

### Claim 8 (depends on 7)

The compound as claimed in claim 7, wherein the live primary cells are selected from a group consisting of fibroblast cells, stem cells and a combination thereof; wherein the stem cells are selected from a group consisting of embryonic stem cells, adult stem cells and a combination thereof; and wherein the induced pluripotent cells (iPCs) are selected from a group consisting of human induced pluripotent stem cells (hiPSCs), mouse induced pluripotent stem cells (miPSCs), induced pluripotent stem cells from any other animal and combinations thereof.

### Claim 9 (depends on 1)

A method of imaging mitochondria in eukaryotic cells, tissues or animals comprising: contacting the eukaryotic cells, tissues or animals with the compound of Formula I as defined in claim 1 to stain the mitochondria and imaging the mitochondria.

### Claim 10 (depends on 9)

The method as claimed in claim 9, wherein the imaging is fluorescence imaging.

### Claim 11 (depends on 9)

The method as claimed in claim 9, further comprising sensing local ordering or viscosity of the mitochondria, tracking the mitochondrial mobility, and dynamics or combinations thereof.

### Claim 12 (depends on 11)

The method as claimed in claim 11, wherein the sensing of said local ordering or viscosity is performed by measuring fluorescence intensity, fluorescence life time, or a combination thereof.

### Claim 13 (depends on 12)

The method as claimed in claim 12, further comprising evaluating mitochondrial function by said sensing of the local ordering or viscosity of the mitochondria.

### Claim 14 (depends on 11)

The method as claimed in claim 11, wherein the tracking of mitochondrial mobility and dynamics is performed by time-lapse imaging using repeated photo illumination.

### Claim 15 (depends on 11)

The method as claimed in claim 11, further comprising evaluating a state, a function, or a combination thereof of the cells or tissues by said mitochondrial imaging.

### Claim 16 (depends on 15)

The method as claimed in claim 15, further comprising identifying or screening a disease condition by evaluating changes in said state, function or a combination thereof of said cells or tissues.

### Claim 17 (depends on 9)

The method as claimed in claim 9, wherein the eukaryotic cells are live primary cells, induced pluripotent cells (iPCs) or a combination thereof; wherein the eukaryotic cells are from human origin, mouse origin or other animal origin; and wherein the eukaryotic cells are selected from a group consisting of cells in culture, cultured cells, cells from tissue and combinations thereof.

### Claim 18 (depends on 17)

The method as claimed in claim 17, wherein the live primary cells are selected from a group consisting of fibroblast cells, stem cells and a combination thereof; wherein the stem cells are selected from a group consisting of embryonic stem cells, adult stem cells and a combination thereof; and wherein the induced pluripotent cells (iPCs) are selected from a group consisting of human induced pluripotent stem cells (hiPSCs), mouse induced pluripotent stem cells (miPSCs), induced pluripotent stem cells from any other animal and combinations thereof.

### Claim 19 (depends on 9)

The method as claimed in claim 9, wherein the method of imaging mitochondria in the eukaryotic cells comprises:
a) contacting the cells with the compound of Formula I by adding a cell culture medium containing the compound to the cells,
b) incubating the cells for a time-period ranging from about 5 minutes to about 48 hours,
c) optionally, washing off the excess compound and adding a fresh cell culture media, to obtain stained cells, and
d) imaging the stained cells by fluorescence microscope.
